Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 9/20 | 0.52 |
| ▸ | RXRA | P19793 | 5/20 | 0.47 |
| ▸ | RXRB | P28702 | 4/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NR4A2 | P43354 | 4/20 | 0.44 |
| ▸ | NR4A1 | P22736 | 2/20 | 0.44 |
| ▸ | NR4A3 | Q92570 | 2/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.42 |
| ▸ | C5 | P01031 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6232546 | 0.89 | GSK3B (0.47) | PPARDRXRARXRBMEN1KMT2A | |
| SCHEMBL11279704 | 0.88 | PTGS2 (0.51) | PPARDRXRARXRBNR4A2NR4A1 | |
| SCHEMBL6538975 | 0.87 | PPARD (0.49) | PPARDRXRARXRBMEN1KMT2A | |
| SCHEMBL6231803 | 0.86 | PPARD (0.54) | PPARDRXRARXRBMEN1KMT2A | |
| SCHEMBL6540399 | 0.86 | PPARD (0.54) | PPARDRXRARXRBMEN1KMT2A | |
| SCHEMBL14384222 | 0.84 | PPARD (0.49) | PPARDRXRARXRBNR4A2NR4A1 | |
| SCHEMBL6539938 | 0.82 | NR4A2 (0.69) | PPARDRXRARXRBNR4A2NR4A1 | |
| SCHEMBL11280862 | 0.82 | PPARD (0.53) | PPARDRXRARXRBNR4A2NR4A1 | |
| SCHEMBL6539023 | 0.82 | L3MBTL1 (0.48) | PPARDRXRARXRBMEN1KMT2A | |
| SCHEMBL3092563 | 0.81 | PPARD (0.53) | PPARDRXRARXRBNR4A2NR4A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011125836-A1 | THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR FIBROMYALGIA | 東レ株式会社 (JP) | 2011-10-13 | — | — | WO | disclosed |
| US-20070244130-A1 | Compounds and Compositions as Ppar Modulators | IRM LLC (BM) | 2007-10-18 | — | — | US | disclosed |
| US-20070244130-A1 | Compounds and Compositions as Ppar Modulators | IRM LLC (BM) | 2007-10-18 | — | — | US | disclosed |
| US-20070244130-A1 | Compounds and Compositions as Ppar Modulators | IRM LLC (BM) | 2007-10-18 | — | — | US | disclosed |
| EP-1749003-A1 | COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS | IRM LLC (BM) | 2007-02-07 | — | — | EP | disclosed |
| WO-2005116016-A1 | COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS | IRM LLC (BM) | 2005-12-08 | — | — | WO | disclosed |
| US-20040157891-A1 | Inhibitor of cox | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157891-A1 | Inhibitor of cox | PTGS1, PTGS2, PTGES2 | PPARD 1747/4885RXRA 1352/4885RXRB 1507/4885 |
| US-20070244130-A1 | Compounds and Compositions as Ppar Modulators | PPARG, PPARA, PPARD | PPARD 3/4885RXRA 9/4885RXRB 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.